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Abstract
Objectives: Hyperglycemia is a predictor for poor stroke outcome. Hyperglycemic stroke 
patients treated with thrombolysis have an increased risk of intracranial hemorrhage. 
Insulin is the gold standard for treating hyperglycemia but comes with a risk of 
hypoglycemia. Glucagon like peptide-1 receptor agonists (GLP-1RA) are drugs used in type 2 
diabetes that have a low risk of hypoglycemia and have been shown to exert neuroprotective 
effects. The primary objective was to determine whether prehospital administration of the 
GLP-1RA exenatide could lower plasma glucose in stroke patients. Secondary objective was 
to study tolerability and safety. 
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Materials & Methods: Randomized controlled trial comparing exenatide administrated 
prehospitally with a control group receiving standard care for hyperglycemia. Patients with 
Face Arm Speech Test ≥1 and glucose ≥8 mmol/L were randomized. Glucose was monitored 
for 24 hours. All adverse events were recorded. 
Results: 19 patients were randomized, 8 received exenatide. An interim recruitment failure 
analysis with subsequent changes of the protocol was made. The study was stopped 
prematurely due to slow inclusion. No difference was observed in the main outcome of 
plasma glucose at 4h; control vs. exenatide [mean, SD] (7.0 ± 1.9 vs. 7.6 ± 1.6; p=0.56). No 
major adverse events were reported. 
Conclusions: We found no evidence that prehospital exenatide had effect on hyperglycemia. 
However, it was given without adverse events in this study with limited sample size that was 
prematurely stopped due to slow inclusion. 
Clinical Trial Registration: “PROLOGUES - Prehospital lowering of glucose in Stroke”, URL: 
www.clinicaltrialsregister.eu (2011-002780-16). 
Keywords: Emergency medical services, ambulances, stroke, diabetes mellitus, glucagon-
like peptide 1, hyperglycemia.
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Introduction
Stroke, of which ischemic stroke account for around 80%, is the second most common cause 
of mortality and the third most common cause of disability.1,2 Diabetes is a well-established 
risk factor for stroke incidence, poor outcome after stroke, and risk for recurrent stroke.3-5 
Approximately one third of patients suffering an ischemic stroke have diabetes in 
international studies.5 In the national Swedish Stroke Registry the numbers are somewhat 
lower with 22% of patients having diabetes.6 
Admission hyperglycemia is, independently from diabetes, a negative 
prognostic marker for patients suffering acute ischemic stroke. Interestingly, hyperglycemia 
in patients without previously known diabetes is associated with a greater risk for poor 
outcome compared to patients with identified diabetes prior the stroke.5,7,8 Trials addressing 
hyperglycemia with early onset insulin treatment have, however, failed to show any benefit 
on the outcome of stroke.9,10 Additionally, several of these trials report a high incidence of 
hypoglycemia.11 
Glucagon-like peptide-1 receptor agonists (GLP-1RA) is a class of anti-
hyperglycemic drugs that reduce glucose in a glucose-dependent manner with a minimal 
risk for hypoglycemia.12-14 Epidemiologic studies have shown that treatment with GLP-1RA 
reduces the risk for major cardiovascular events and large randomized clinical trials have 
confirmed this finding.15-20 There is a growing body of evidence from preclinical studies 
using experimental stroke models that GLP-1RA treatment can also reduce stroke-induced 
brain damage both under hyper- and normoglycemic conditions.21-26 Most studies have used 
pre-treatment, but effect has also been shown with administration after stroke.22 It is 
undetermined whether treatment with GLP-1RA can affect the clinical outcome after 
ischemic stroke in humans.27
Aims
To date there are no clinical trials that have reported the efficacy and feasibility of GLP-1RA 
prehospital administration on patients admitted to hospital for stroke.
The triad of antihyperglycemic effects, minimal risk of hypoglycemia and 
neuroprotection makes GLP-1RA an extremely interesting treatment option in patients A
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exposed to ischemic stroke and hyperglycemia. We therefore designed this study evaluating 
safety and feasibility of treatment with the GLP-1RA exenatide in a prehospital setting. The 
primary endpoint was a reduction in plasma glucose of 2.0 mmol/L after 4 hours. The 
secondary endpoint was safety of prehospital administration of exenatide in acute stroke 
(adverse events e.g. hypoglycemic episodes or problems reported by the ambulance nurse). 
Materials & Methods
Trial design and oversight
The study was an open label randomized controlled trial comparing prehospital exenatide 
treatment started in ambulance compared to standard care (i.e. insulin treatment at 
hospital). The study was approved by the Central Ethics Committee of Sweden (Ref. No. Ö 6-
2012). Written informed consent was obtained in the ambulance from all participants. 
Patients were randomized in a 1:1 ratio in randomization blocks of 4. The decentralized 
organization of the ambulance service ensured that the ambulance nurses had no knowledge 
about previous randomization results. The study center was Södersjukhuset in Stockholm, 
Sweden: a large urban teaching hospital that treats approximately 1000 patients every year 
for ischemic stroke out of which around 75 % arrive by ambulance. The protocol was 
published prior to the start of the trial on clinicaltrialsregister.eu (EudraCT number: 2011-
002780-16). Two changes to the protocol was added after start of study: 1) widening of 
glucose inclusion criteria from 10-15 mmol/L to first 9-15 mmol/L and then 8-15 mmol/L 
and 2) inclusion of patients with previously known metformin treated type 2 diabetes. These 
changes were made due to slow recruitment. 
Patients
Patients transported to hospital by ambulance with symptoms of stroke and hyperglycemia 
were considered eligible for the study. Inclusion criteria was: ≥ 1 point on the FAST-test 28 
(Face Arm Speech Time), symptoms of stroke with a duration less than 6 hours, capillary 
plasma glucose 8-15 mmol/L, age ≥18 and signed informed consent. Exclusion criteria were: 
type 1 diabetes, antidiabetic treatment other than metformin, pregnancy, cirrhotic liver 
disease, regular hemo- or peritoneal dialysis, GCS < 14 or GCS verbal < 5, signs of pharyngeal 
palsy or previously known dementia. 
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Procedures and outcomes
Patients were screened and included by the registered prehospital nurse. 90 nurses were 
trained and individually delegated to include patients. Study physician (ML) was on call 
around the clock for consultations throughout the study period. Patients randomized to 
exenatide received a single subcutaneous injection of 10 µg exenatide in the ambulance en-
route to hospital. Patients randomized to standard care received no study treatment in the 
ambulance. Patients were kept fasting the first 4 hours to achieve stable and comparable 
conditions. Venous samples were collected before treatment and after 4 and 24 hours. 
Capillary glucose measurements were made every hour for the first 4 hours, then every 4 
hours until end of study. Total study period was 24 hours. Insulin on a sliding scale was used 
for comparator, except for the first 4 hours. Insulin could, however, be administered at any 
time by the treating physician if considered clinically important. Adverse events and insulin 
use was recorded in the case report form.
To achieve reliable and comparable capillary measurements a high precision 
glucometer, Accu-Chek® Inform II (Roche Diagnostics, Rotkreuz, Switzerland) was chosen as 
primary glucometer in the study, this glucometer also allowed for automated data transfer to 
a server.29 In case the Accu-Chek® Inform II was non-operational the regular glucometer at 
the point of care was used instead. Venous plasma glucose was measured at a core lab 
facility, The Karolinska University laboratory, with the hexokinase method on cobas® 8000 
(c701), Roche Diagnostics. 
Primary outcome was a reduction of plasma glucose with 2.0 mmol/L at 4 hours 
after randomization. Secondary outcomes were: overall feasibility of prehospital treatment 
(adverse events and problems reported by the ambulance nurses), and as an exploratory 
post hoc outcome the AUC of glucose during 4 and 24 hours. 
Statistical analysis
Power calculation gave a sample size of 42 to detect a 2 mmol/L difference in plasma glucose 
at 4 hours with a power of 90% and a two-sided alpha level of 0.05. 
The differences in 4 hour P-glucose, AUC of glucose during the first 4 hours and 
during the total study period of 24 hours were analyzed with Mann-Whitney U-test. AUC of 
glucose was calculated with the trapezoid formula. Missing data on capillary glucose for the 
AUC calculations was handled with imputation of mean value of adjacent time points. A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved
Individuals with ≤ 40 % valid measurements were excluded (n=2, 1 exenatide and 1 
control). An additional analysis was made with linear regression adjusting for sex, age and 
BMI. Analyses presented are made according to Intention To Treat (ITT) 
SPSS v23.0.0.3 (IBM Corp, Armonk, NY, USA) was used for statistical analysis. A 
two sided p-value <0,05 was considered statistically significant.
Results
Overview of study
The study was open for inclusion between May 2013 and May 2018 and was stopped due to 
slow inclusion. A total of 19 patients were included in the study, 8 received exenatide. One 
patient was transferred to a tertiary center for thrombectomy. That record was obtained 
retrospectively and evaluated for outcomes and adverse events. Baseline characteristics are 
shown in table 1. 
Recruitment failure analysis
An analysis of recruitment failure was made in 2015 due to slow inclusion. The largest 
participating ambulance station responsible for approximately 25 % of the ambulance 
transports to the study hospital and 50 % of the study ambulances was reviewed. Among the 
non-included patients during the first four months of 2015 a total of 143 dispatches were 
made for suspected stroke. The suspicion remained in 69 patients after initial ambulance 
nurse evaluation. Out of them 13 patients had a glucose value of 9-15 mmol/L, which was 
the inclusion range at time of review. Two of these patients met all criteria and could have 
been included and was as such true recruitment failures. 
The remaining eleven patients would have been excluded mainly due to 
problems with obtaining informed consent; three were confused, two had reduced level of 
consciousness, one had hearing impairment and one needed morphine for pain control. 
Three patients did not meet the inclusion criteria and one was deemed non suitable by the 
ambulance nurse (ambulance transit time 3 minutes). 
With a glucose inclusion interval of 8-15 mmol/L the 13 patients would have 
increased to 19.  As a result of this analysis the glucose interval for inclusion was expanded 
to 8-15 mmol/L. 
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Glucose outcomes
There was no difference between the exenatide treated group and the control group in p-
glucose levels at 4 hours (7.6 vs. 7.0, P=0.56), Table 2. Total glucose exposure measured with 
AUC showed no difference: AUC 0-4h (33.7 vs. 32.9, P=0.93) or AUC 0-24h (186.8 vs. 184.3, 
P=0.90), Figure 1.
On the main outcome variable, venous p-glucose at 4 hours, data was missing 
for 3 individuals (2 exenatide, 1 control). The primary analysis is without imputation. A 
sensitivity analysis with the capillary values imputed for venous did not change the results 
significantly. Linear regression of venous glucose at 4 hours with adjustment for age, sex and 
BMI resulted in similar results (exenatide vs. control: 7.1 vs. 7.4, P=0.76). Sensitivity 
analyses for AUC-measures with either the highest or lowest adjacent values imputed were 
made, but did not alter the results. 
Analyses including only individuals with stroke diagnoses at discharge were 
performed for all analyses but did not alter the results significantly (data not shown). 
Insulin treatment
No insulin was administrated during the study period as the criterion for insulin treatment 
was not met for any individual.
Adverse events
No major adverse events were observed during the study period. One patient in the 
exenatide group suffered from nausea and vomiting. However, that participant suffered from 
basilar thrombosis and had vomited before inclusion. No patients experienced 
hypoglycemia. 
Discussion
Preclinical studies showing favorable effects of GLP-1RA in stroke encourage clinical studies 
of these diabetes drugs for stroke treatment.27 However, the clinical efficacy of acute 
neuroprotection after stroke is largely dependent on timely intervention within a very short 
therapeutic window to minimize stroke-induced brain loss (few hours from stroke onset), 
which is very difficult to achieve. To gain new knowledge in this field, this study was 
designed as a pilot to investigate whether it was possible and safe to administer exenatide in 
a prehospital setting and lower plasma glucose. Our study found no evidence that A
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prehospital exenatide lowered glucose levels in acute stroke, but that it was feasible to 
perform without any serious adverse events or hypoglycemia. However, as the study was 
prematurely closed due to slow inclusion, it also shows the difficulty of this type of study. 
Both the exenatide and the control groups were hyperglycemic in the first hours 
post stroke onset, but the glucose level dropped equally. The initial hyperglycemia may have 
been caused by stress hyperglycemia, which is known to be present after stroke.7,11 
The exenatide group also had higher NIHSS-score compared with the control 
group (median 4.5 vs. 1). Larger strokes could potentially produce higher stress levels and 
cause a more severe stress hyperglycemia that could mask out a potential treatment effect. 
Some patients only had moderate levels of hyperglycemia as the inclusion threshold was 8 
mmol/L making detection of glucose reduction harder. The statistical phenomenon 
“regression to mean” could also play a role as all patients included were selected on the basis 
of an abnormal lab value, i.e. hyperglycemia. 
Another potential reason for low effect we cannot rule out is decreased 
bioactivity of exenatide in the ambulances since storage of the drug was in the ambulances 
with potentially varying temperatures. However, the prefilled exenatide syringes were 
exchanged continuously before expiration date throughout the study period and were stored 
in an insulating casein the ambulances. Considering both that the study drug was 
continuously exchanged and was stored in a protected manner in the ambulances we 
consider the risk of significant degradation of exenatide to be low. 
One of the most common side effects in clinical use of GLP-1RA is nausea and 
vomiting.30,31 In our study one patient experienced these symptoms. That patient suffered 
from a basilar thrombosis and was vomiting before randomization to exenatide. Hence, no 
patients in our study experienced GLP-1RA induced nausea. Vomiting from clinical use of 
GLP-1RA could in part be mediated by slowed gastric emptying.32 In the acute phase of 
stroke nil per os is often ordered before oropharyngeal function is known, simultaneously 
reducing this potential problem of GLP-1RA side effects. As our study demonstrated that 
exenatide can be administrated in this vulnerable group of patients with very few reported 
adverse events including nausea and vomiting, we suggest that GLP-1RA agonists is a safe 
potential treatment option on stroke patients even with potential pharyngeal palsy. 
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Our study was stopped early due to slow inclusion. As it is of paramount 
importance that study subjects understand the concept of the study and can give an 
informed consent to participate, the present study in a study-population with high risk for 
cognitive impairment and aphasia present a great challenge in this regard. Therefore a large 
number of patients with aphasia and suspected cognitive dysfunction were excluded from 
participation in the study. This was also shown by our recruitment failure analysis where 
only 13 of 143 cases of suspected stroke remained with good fit for the study. Moreover, the 
importance of reducing time to rtPA treatment may have stressed the ambulance nurses to 
not include potential study subjects in the prehospital setting. The most important reason 
for not being eligible for inclusion was, however, the glucose range. Even mild 
hyperglycemia was relatively uncommon with 13 of 69 patients having the stipulated 
glucose range of 9-15 mmol/L. This resulted in an amendment to the protocol to expand the 
range to 8-15 mmol/L. Another obstacle to maintaining inclusion was the turnover of nurses 
working at the participating stations. Because inclusion in the ambulance could only be 
made by a nurse delegated to do so, every time a nurse changed employer a new one had to 
be trained and delegated or potential patients would be missed. In total 90 nurses received 
study training and individual delegation. 
There are several limitations of the study. The most important shortcoming of 
the study is the low number of included patients. The limited sample size warrants some 
caution in interpretation of the lack of adverse events as a lower frequency than 35% cannot 
be expected to be detected.33 Another limitation is the short follow-up of 24 hours. Finally, as 
inclusion in the study was prehospital some of the included patients were found to have 
other discharge diagnoses than stroke. 
However, the real world situation for ambulance nurses is one of uncertainty 
with a lack of background information, labs and no x-ray. This makes transfer of protocols 
developed in a hospital arena to the prehospital setting hard. The fact that our study was 
performed in a real prehospital setting without adverse events is promising, but the limited 
study sizes makes it impossible to draw definitive conclusions about safety. 
Our study could not, and was not designed to, determine if early treatment with 
GLP-1RA could reduce poor outcome after stroke. Importantly, GLP-1RA have been shown to 
be neuroprotective in animal studies under normoglycemic conditions even with treatment 
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initiated early after stroke.22 Therefore, larger studies evaluating other GLP-1RA than 
exenatide with a focus on clinical outcomes after stroke should be launched in a near 
future.27
Conclusion
The present study found no evidence to suggest that prehospital treatment with exenatide 
on patients with stroke symptoms lowers preexisting mild hyperglycemia. On the other 
hand, administration of exenatide was not associated with adverse events or other 
problems. The study was stopped prematurely due to slow recruitment of patients that was 
caused by narrow inclusion and exclusion criteria in combination with the difficulties posed 
by including patients with stroke in a prehospital environment. 
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Tables
Table 1. Baseline characteristics of study participants (Control N=11, Exenatide N=8)
Data is presented as median with interquartile range unless otherwise specified. 
IQR = interquartile range, BMI = body mass index, cP-Glucose = capillary plasma glucose, vP-
Glucose = venous plasma glucose, NIHSS = National Institutes of Health Stroke Scale, rtPA = 
recombinant tissue Plasminogen Activator. 
Table 2. Outcome measures (Control N=11, Exenatide N=8)
Control ± SD Exenatide ± SD P 
vP-Glucose 4 h, 
mmol/L
7.0 ± 1.9 7.6 ± 1.6 0.56
Control (IQR) Exenatide (IQR)
Age, years 80 (63-89) 71 (54-82)
Male sex, n (%) 6 (55) 4 (50)
BMI, kg/m2 26.4 (23.2 – 31.7) 27.2 (21.6 – 29.5)
cP-Glucose, mmol/L 9.6 (9.0-10.8) 9.6 (8.4-10.6)
vP-Glucose, mmol/L 9.4 (7.9-11.2) 8.8 (6.9-10.9)
Systolic blood pressure, 
mmHg
165 (130-190) 150 (124-175)
Diastolic blood pressure, 
mmHg
89 (80-100) 80 (76-98)
Heart rate 88 (72-90) 80 (68-89)
NIHSS 1 (0-4) 4.5 (1-8)
Discharge diagnosis
    Ischemic Stroke, n 9 4
    Hemorrhagic Stroke, n 0 2
    Non-Stroke, n 2 2
Treated with rtPA 1 0
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved
cP-Glucose 4 h, mmol/L 6.5 ± 1.5 7.3 ± 2.0 0.62
AUC 0-4 h, glu x h 32.9 ± 6.2 33.7 ± 9.6 0.93
AUC 0-24h, glu x h 184.3 ± 41 186.8 ± 40 0.90
Adverse events, n 0 1†
Need of insulin, n 0 0
†Nausea and vomiting first 24 h, patient suffered from basilar thrombosis. Data presented as 
means ± standard deviation. vP-Glucose = venous plasma glucose, cP-Glucose = capillary 
plasma glucose. Variables tested with Mann-Whitney U-test. 
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Figure Legends
Figure 1. Capillary plasma glucose. P-values in figure represent Mann-Whitney U-test of AUC 
0-4h and 0-24h. Bars indicate standard deviation. 
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Figure 1. Capillary plasma glucose. P-values in figure represent Mann-Whitney U-test of 
AUC 0-4h and 0-24h. Bars indicate standard deviation.  
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